Download or read book Tumor Antigens Recognized by T Cells and Antibodies written by Hans J Stauss and published by CRC Press. This book was released on 2003-01-23 with total page 220 pages. Available in PDF, EPUB and Kindle. Book excerpt: Recent progress in fundamental tumor immunology has led to immunotherapy trials in patients with solid tumors and hematological malignancies. In the past, immunotherapy approaches were primarily based on enhancement of tumor immunity with cytokines and adjuvant therapy, without knowledge of relevant tumor antigens. The discovery of tumor antigens c

Download or read book Vaccines for Cancer Immunotherapy written by Nima Rezaei and published by Academic Press. This book was released on 2018-10-17 with total page 200 pages. Available in PDF, EPUB and Kindle. Book excerpt: Therapeutic cancer vaccines represent a type of active cancer immunotherapy. Clinicians, scientists, and researchers working on cancer treatment require evidence-based and up-to-date resources relating to therapeutic cancer vaccines. Vaccines for Cancer Immunotherapy provides a reference for cancer treatment for clinicians and presents a well-organized resource for determining high-potential research areas. The book considers that this promising modality can be made more feasible as a treatment for cancer. Chapters cover cancer immunology, general approaches to cancer immunotherapy, vaccines, tumor antigens, the strategy of allogeneic and autologous cancer vaccines, personalized vaccines, whole-tumor antigen vaccines, protein and peptide vaccines, dendritic cell vaccines, genetic vaccines, candidate cancers for vaccination, obstacles to developing therapeutic cancer vaccines, combination therapy, future perspectives and concluding remarks on therapeutic cancer vaccines. - Introduces the feasible immunotherapeutic vaccines for patients with different types of cancer - Presents the status of past and current vaccines for cancer treatment - Considers advantages and disadvantages of different therapeutic cancer vaccines - Looks at the combination of vaccines and other modalities, including immunotherapeutic and conventional methods - Analyzes obstacles to development of therapeutic cancer vaccines - Gives a view on future perspectives in the application of therapeutic cancer vaccines

Download or read book Tumor Immunology and Immunotherapy written by Robert C. Rees and published by Oxford University Press, USA. This book was released on 2014 with total page 469 pages. Available in PDF, EPUB and Kindle. Book excerpt: Tumor immunology and immunotherapy provides a comprehensive account of cancer immunity and immunotherapy. Examining recent results, current areas of interest and the specific issues that are affecting the research and development of vaccines, this book provides insight into how these problems may be overcome as viewed by leaders in the field.

Download or read book Janeway s Immunobiology written by Kenneth Murphy and published by Garland Science. This book was released on 2010-06-22 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: The Janeway's Immunobiology CD-ROM, Immunobiology Interactive, is included with each book, and can be purchased separately. It contains animations and videos with voiceover narration, as well as the figures from the text for presentation purposes.

Download or read book Molecular Biology of the Cell written by and published by . This book was released on 2002 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Tumor Immunology written by Giorgio Parmiani and published by CRC Press. This book was released on 2002-04-25 with total page 224 pages. Available in PDF, EPUB and Kindle. Book excerpt: Recent advances in immunology and molecular biology have resulted in new therapeutic approaches being generated and implemented in cancer clinics. The discovery of new antigens, mechanisms of antigen presentation, and interplay of cells involved in anti-tumor immunity have made the clinical control of some cancers more plausible than previously tho

Download or read book Medicinal Chemistry of Anticancer Drugs written by Carmen Avendaño and published by Elsevier. This book was released on 2015-06-11 with total page 767 pages. Available in PDF, EPUB and Kindle. Book excerpt: Medicinal Chemistry of Anticancer Drugs, Second Edition, provides an updated treatment from the point of view of medicinal chemistry and drug design, focusing on the mechanism of action of antitumor drugs from the molecular level, and on the relationship between chemical structure and chemical and biochemical reactivity of antitumor agents. Antitumor chemotherapy is a very active field of research, and a huge amount of information on the topic is generated every year. Cytotoxic chemotherapy is gradually being supplemented by a new generation of drugs that recognize specific targets on the surface or inside cancer cells, and resistance to antitumor drugs continues to be investigated. While these therapies are in their infancy, they hold promise of more effective therapies with fewer side effects. Although many books are available that deal with clinical aspects of cancer chemotherapy, this book provides a sorely needed update from the point of view of medicinal chemistry and drug design. - Presents information in a clear and concise way using a large number of figures - Historical background provides insights on how the process of drug discovery in the anticancer field has evolved - Extensive references to primary literature

Download or read book Human Tumor Antigens and Specific Tumor Therapy written by Malcolm S. Mitchell and published by . This book was released on 1989 with total page 394 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Tumor Immunology written by and published by . This book was released on 1995 with total page 268 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Chimeric Antigen Receptor T Cell Therapies for Cancer E Book written by Daniel W. Lee and published by Elsevier Health Sciences. This book was released on 2019-11-30 with total page 246 pages. Available in PDF, EPUB and Kindle. Book excerpt: From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. - Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. - Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. - Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. - Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy.

Download or read book Analyzing T Cell Responses written by Dirk Nagorsen and published by Springer Science & Business Media. This book was released on 2006-01-16 with total page 313 pages. Available in PDF, EPUB and Kindle. Book excerpt: Active specific immunotherapy is a promising but investigational modality in the management of cancer patients. Currently, several different cancer vaccine formulations such as peptides, proteins, antigen-pulsed dendritic cells, whole tumor cells, etc. in combination with various adjuvants and carriers are being evaluated in clinical trials (1-3). To determine the optimal cancer vaccine strategy, a surrogate immunological end-point that correlates with clinical outcome needs to be defined, since it would facilitate the rapid comparison of these various formulations. Traditional immunological assays such as ELISA, proliferation and cytotoxicity assays can detect immune responses in vaccinated patients but are not quantitative. In contrast, novel assays such as enzyme-linked immunospot (ELISPOT) assay, intracellular cytokine assay and tetramer assay can quantitate the frequency of antigen-specific T cells. Of these, the ELISPOT assay has the 5 lowest detection limit with 1/10 peripheral blood mononuclear cells (PBMC) and has been determined to be one of the most useful assays to evaluate immune response to cancer vaccines (4). However, the IFN-? ELISPOT assay is not an exclusive measure of cytotoxic T-lymphocyte (CTL) activity as non-cytotoxic cells can also secrete IFN-?. Additionally, CTL with lytic activity do not always secrete IFN-? (5). A more relevant approach to assess functional activity of cytotoxic lymphocytes would be to measure the secretion of molecules that are associated with lytic activity. One of the major mechanisms of cell-mediated cytotoxicity involves exocytosis of cytoplasmic granules from the effector toward the target cell.

Download or read book Translational Immunotherapy of Brain Tumors written by John H. Sampson and published by Academic Press. This book was released on 2017-02-06 with total page 406 pages. Available in PDF, EPUB and Kindle. Book excerpt: Translational Immunotherapy of Brain Tumors gives researchers and practitioners an up-to-date and comprehensive overview of the field. Chapters include adoptive immunotherapy, immunosuppression, CAR therapy of brain tumors, and dendritic cell therapy for brain tumors. Very few agents have been shown to be efficacious in the treatment of malignant gliomas. Recently, there have been a number of studies demonstrating the potential success of immunotherapy for brain tumors. Immunotherapeutics are becoming the most frequent drugs to be used in cancer therapy. These new breakthroughs, now approved by the FDA, are a part of multiple phase III international trials and ongoing research in malignant glioma, meaning that the information in this cutting-edge book will be of great importance to practitioners and researchers alike. Comprehensive overview, providing an update on immunology, translational immunotherapy, and clinical trials relating to malignant gliomas Edited by a prominent neurosurgeon with contributions by leading researchers in the field Ideal resource for researchers and practitioners interested in learning about mechanisms that use the immune system to treat brain tumors

Download or read book General Principles of Tumor Immunotherapy written by Howard L. Kaufman and published by Springer Science & Business Media. This book was released on 2007-10-12 with total page 502 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book brings together the world’s leading authorities on tumor immunology. This book describes the basic immunology principles that form the foundation of understanding how the immune system recognizes and rejects tumor cells. The role of the innate and adaptive immune responses is discussed and the implications of these responses for the design of clinical strategies to combat cancer are illustrated.

Download or read book Monoclonal Antibodies in Cancer written by Stewart Sell and published by Springer Science & Business Media. This book was released on 2012-12-06 with total page 440 pages. Available in PDF, EPUB and Kindle. Book excerpt: This represents the third volume in a series on cancer markers pub lished by the Humana Press. The first volume, published in 1980, stressed the relationship of development and cancer as reflected in the production of markers by cancer that are also produced by normal cells during fetal development. The concept that cancer represents a problem of differentiation was introduced by Barry Pierce in describing differenti ation of teratocarcinomas. Highlighted were lymphocyte markers, alphafetoprotein, carcinoembryonic antigen, ectopic hormones, enzymes and isozymes, pregnancy proteins, and fibronectin. The second volume, published in 1982 and coedited with Britta Wahren, focused on the diagnostic use of oncological markers in human cancers, which were systematically treated on an organ by organ basis. At that time, the application of monoclonal antibodies to the identification of cancer markers was still in a very preliminary stage. A general introduc tion to monoclonal antibodies to human tumor antigens was given there by William Raschke, and other authors included coverage of those mark ers then detectable by monoclonal antibodies in their chapters.

Download or read book Symposium in Immunology VI written by Martha M. Eibl and published by Springer Science & Business Media. This book was released on 2012-12-06 with total page 178 pages. Available in PDF, EPUB and Kindle. Book excerpt: This is the sixth symposium in a series of symposia on immunology organized by IMMUNO covering this time tumor immunology. This volume deals with T cell recognition and CD95-associating signaling, clinical investigations: cells, costimulatory signals and therapeutic approaches: cytokines and vaccines.

Download or read book Model Systems for the Retargeting of T Cell Mediated Immunity to Tumor Antigens written by Erik Robert Wilson and published by . This book was released on 1994 with total page 310 pages. Available in PDF, EPUB and Kindle. Book excerpt: B cells and T cells are involved in the response against foreign antigens. Specificity of B cells is determined by antibodies while the specificity of T cells is determined by similar proteins called T-cell receptors. One function of T cells is surveillance against tumor cells. Progressing tumors have escaped T cell surveillance, but the immune system could still be effective if the T cell immune response could be retargeted against the tumor. A strategy for accomplishing this is the construction of a bispecific antibody which binds a tumor cell antigen and a T-cell receptor, bringing the T cell into contact with the tumor cell and activating the T cell to destroy the tumor cell. A bispecific antibody model system was constructed to examine two questions: First, what is the affinity of the anti-tumor antibody needed to transmit an activation signal to the T cell? Second how many antigens are required on the target cell to activate T cells? The model system utilized fluorescein as a "surrogate" tumor antigen and an anti-fluorescein antibody (4-4-20) as one half of the bispecific antibody (the other half being an anti-T cell receptor antibody). Conjugated forms of fluorescein with nearly a 100-fold range of affinities for 4-4-20 were synthesized and characterized. These fluorescein conjugates were attached to tumor cells as targets at a range of antigen densities. T cell activation was measured by the killing of these target cells. A clear density threshold was established of between 2,000 and 24,000 antigen molecules per cell for the highest-affinity fluorescein conjugate. The density threshold increased to between 19,000 and 54,000 antigen per cell for the next-highest-affinity fluorescein conjugate. The density threshold increased to over 270,000 antigen per cell for the lowest affinity fluorescein conjugate. These antigen densities are within the range seen for many tumor antigens and the affinities are within the range seen for anti-tumor antibodies. The results demonstrate the antibody affinities that should be used when targeting particular tumor antigens in therapy with bispecific antibodies. Because very little is known about T-cell receptor affinity in normal T cell function, another system was developed to address this issue. A chimeric antibody/T-cell receptor was constructed from the variable regions of anti-fluorescein antibody (9-40) and the constant regions of a T-cell receptor with the intention of using it to study affinity and ligand density requirements for the activation of native T cells. DNA for the chimeric receptor was transfected into a T lymphoma. To detect and select for the chimeric receptor, an antibody (4B5) was produced that was specific for the variable regions of antibody 9-40. Antibody 4B5 was attached to magnetic beads and used to select transfectants that expressed the chimeric receptor. The transfectants were shown to bind fluorescein but did not show significant levels of activation upon binding. Nevertheless, the magnetic selection method should be useful in obtaining cells that are transfected with genes that encode multimeric surface proteins such as other chimeric receptors.

Download or read book Tumor Associated Antigens written by Olivier Gires and published by John Wiley & Sons. This book was released on 2009-02-11 with total page 383 pages. Available in PDF, EPUB and Kindle. Book excerpt: The first comprehensive and most recent overview of the topic, this ready reference and handbook reviews current knowledge of TAAs, their subclasses, and pinpoints their application areas in medicine. In addition, it emphasizes target identification procedures, the need for an accurate and thorough analysis of the function of TAAs, and the validation of those in clinical settings. The whole is rounded off with an overview of currently approved therapeutic antibodies. The result is a must-have for biologists and oncologists in science, clinics and industry.